StockNews.AI
BCTX
StockNews.AI
19 days

BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study

1. UCLA Health joins BriaCell’s Phase 3 study on Bria-IMT in metastatic breast cancer. 2. Positive Phase 2 results encourage further exploration of Bria-IMT combination therapy. 3. Study aims for strong patient enrollment to enhance survival outcomes in MBC. 4. Bria-IMT has FDA Fast Track designation, highlighting its potential market impact. 5. Top-line data expected in 2026, with interim analysis after 144 patient events.

7m saved
Insight
Article

FAQ

Why Bullish?

BriaCell’s partnerships with U.S. cancer centers could increase trial enrollment and visibility, similar to past successes seen in other biotech firms that partnered with leading institutions, boosting their stock prices following positive study results. The FDA Fast Track designation also indicates potential market competitiveness, crucial for BCTX’s valuation.

How important is it?

The article discusses a pivotal Phase 3 study and meaningful partnerships that bolster BriaCell’s credibility and prospects, indicating a considerable chance of impacting BCTX’s stock price positively as developments unfold.

Why Long Term?

With top-line data anticipated in 2026, investors may see a more accurate reflection of the company’s potential over the long term, similar to other biotech firms like Moderna that benefited from extended development timelines. Early positive trial data can continuously impact the stock as it gathers momentum.

Related Companies

MRNAEDITZGEN
July 31, 2025 07:30 ET  | Source: BriaCell Therapeutics Corp. PHILADELPHIA and VANCOUVER, British Columbia, July 31, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces the addition of UCLA Health Jonsson Comprehensive Cancer Center, a leading cancer center in California, to its ongoing pivotal Phase 3 clinical study (Bria-ABC, NCT06072612) evaluating Bria-IMT™ in combination with a checkpoint inhibitor versus physician’s choice in patients with advanced metastatic breast cancer (MBC). “The randomized Phase 2 data reported with the Bria-IMT combination regimen are encouraging, and we believe BriaCell’s Phase 3 study represents an opportunity for meaningful progress towards improving survival outcomes in patients with metastatic breast cancer,” stated Kelly E. McCann, MD, PhD, Breast Medical Oncologist, and Lead Investigator at UCLA Health Jonsson Comprehensive Cancer Center. “We are excited to support this important study and anticipate strong patient enrollment through our large multi-center clinical site.” “The inclusion of UCLA Health underscores our strategy to partner with top-tier institutions to accelerate trial enrollment and execution,” said Dr. Giuseppe Del Priore, BriaCell’s Chief Medical Officer. “We remain confident in our timeline for sharing top-line data in 2026.” Interim analysis of the pivotal Phase 3 study will be conducted after 144 patient events (deaths) have occurred, with overall survival (OS) as the primary endpoint. The study compares the Bria-IMT combination regimen with immune checkpoint inhibitor against physician’s choice in patients with advanced metastatic breast cancer. This design builds upon maturing positive survival data from BriaCell’s Phase 2 study, most recently presented at ASCO 2025, which evaluated the same combination in a similar MBC patient population. Notably, the Bria-IMT combination regimen has been granted FDA Fast Track designation, underscoring its potential to address a serious unmet medical need. For additional information on BriaCell’s pivotal Phase 3 study of Bria-IMT and an immune check point inhibitor in metastatic breast cancer, please visit ClinicalTrials.gov NCT06072612. About BriaCell Therapeutics Corp. BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/. Safe Harbor This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those about BriaCell’s Phase 3 study representing an opportunity for meaningful progress towards improving survival outcomes in patients with metastatic breast cancer; the Company’s anticipated strong patient enrollment through their large multi-center clinical site; the Company’s anticipated timeline for sharing top-line data; and the Company’s timeline for its analysis of interim data are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading “Risks and Uncertainties” in the Company’s most recent Management’s Discussion and Analysis, under the heading “Risk Factors” in the Company’s most recent Annual Information Form, and under “Risks and Uncertainties” in the Company’s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company's profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law. Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release. Contact Information Company Contact:William V. Williams, MDPresident & CEO1-888-485-6340info@briacell.com  Investor Relations Contact:investors@briacell.com

Related News